申请人:ZENECA LIMITED
公开号:EP0632016A1
公开(公告)日:1995-01-04
The invention concerns acid derivatives of formula I
R¹-CON(R²)-N(R³)CO-X¹-Q-X²-G I
and pharmaceutically acceptable metabolically labile esters or amides thereof, and pharmaceutically acceptable salts thereof, wherein R¹ represents a group of formula II or III
in which A is attached meta or para to the position where the group CONR²NR³CO is attached and is selected from aminomethyl, guanidino and RaN=C(NH₂)-
T is N or CH, and
X³ is a bond, (1-4C)alkylene or, when T is CH, oxy(1-3C)alkylene;
R² and R³, which may be the same or different, represent hydrogen, (1-4C)alkyl or ar(1-4C)alkyl;
X¹ is a bond or (1-4C)alkylene;
Q is a group of formula IV or V
X² is a bond, (1-4C)alkylene, oxy(1-3C)alkylene or a group of formula CH₂CH(NHXR⁴) in which X is SO₂, CO or CO₂ and R⁴ is (1-6C)alkyl, (6-12C)aryl or (6-12C)aryl(1-4C)alkyl in which the aryl group may optionally be substituted by (1-4C)alkyl; and
G is a carboxy group.
The invention also concerns processes for the preparation of the acid derivatives of formula I, pharmaceutical compositions containing them and their use as inhibitors of the binding of fibrinogen to glycoprotein IIb/IIIa.
本发明涉及式 I 的酸衍生物
r¹-con(r²)-n(r³)co-x¹-q-x²-g i
及其药学上可接受的代谢性酯或酰胺,以及其药学上可接受的盐,其中 R¹ 代表式 II 或 III 的基团
其中 A 连接至连接基团 CONR²NR³CO 的位置的元或对位,且选自氨基甲基、胍基和 RaN=C(NH₂)-
T 是 N 或 CH,以及
X³ 是键、(1-4C)亚烷基或当 T 是 CH 时,氧(1-3C)亚烷基;
R² 和 R³ 可以相同或不同,代表氢、(1-4C)烷基或 ar(1-4C)烷基;
X¹ 是键或(1-4C)亚烷基;
Q 是式 IV 或 V 的基团
X² 是键、(1-4C)亚烷基、氧基(1-3C)亚烷基或式 CH₂CH(NHXR⁴)的基团,其中 X 是 SO₂、CO 或 CO₂,R⁴ 是(1-6C)烷基、(6-12C)芳基或(6-12C)芳基(1-4C)烷基,其中芳基可任选被(1-4C)烷基取代;以及
G 是羧基。
本发明还涉及式 I 酸衍生物的制备工艺、含有它们的药物组合物以及它们作为纤维蛋白原与糖蛋白 IIb/IIIa 结合的抑制剂的用途。